Researchers looked at cardiac fibrosis, which can occur in patients who have suffered an infection of the heart muscle or a heart attack. Such fibrosis causes the heart to stiffen so that it cannot adequately fill with blood and then empty itself, a condition known as diastolic dysfunction.
Ads by Google
Beating heart CABG saved $1,684 per procedure, inclusive of the cost of the C-Port systems in the beating heart cases, compared to traditional bypass surgery.
Boston Scientific Corporation has received approval for the sale of its TAXUS Liberte paclitaxel-eluting coronary stent system in Canada. The Company reported that Health Canada's Therapeutic Products Directorate (TPD), the authority that regulates pharmaceutical drugs and medical devices, has approved its use. The Company said it plans to launch the product immediately in Canada.
Before gene therapy becomes practical for treating human diseases, researchers must master the details of safe and effective delivery. Cardiology researchers at The Children's Hospital of Philadelphia have advanced delivery techniques by creating a versatile synthetic material that can bind to a variety of gene therapy vectors and can be custom-designed for controlled local release of therapeutic genes at a disease site.
Polar's patented OwnCode technology - previously only available in Polar heart rate monitors - can now be seamlessly and cost-effectively incorporated into commercial fitness equipment, putting it within reach of thousands of manufacturers and health club owners alike.
ImmuKnow values appear to closely reflect the immune function of the heart transplant recipient and patient risk for organ rejection and/or infection.
A new drug therapy designed to lower risk of heart attack, stroke or death following heart bypass surgery has failed to meet its goals.
CV Therapeutics announced that Ranexa significantly reduced the risk of recurrent ischemia, worsening angina and intensification of antianginal therapy in angina patients in the MERLIN- TIMI 36 study.
Given the recent investigation by the US Department of Justice into the marketing of biliary stents for off-label uses in the peripheral vasculature, obtaining FDA approval for device use in specific arteries could become a key focus for stent manufacturers.
MyoCell myoblast clinical cell therapy is a safe and potentially effective alternative treatment to standard medical therapy alone for improving heart function among patients with previously implanted cardiac devices who are experiencing congestive heart failure.
CardioMind has begun a First-in-Human clinical trial of its drug-eluting stent.
MICARDIS is equally effective as the current standard, ramipril, in reducing the risk of cardiovascular death, myocardial infarction, stroke and hospitalization for congestive heart failure.
Life-saving skills is in your hands with Hands-Only CPR, as American Heart Association says don't be afraid and help bystander's life with CPR.
American Heart Association says that CPR is a life saving action and it should only be done with hands.
Greater amounts of calcium deposits in a person's arteries, as measured by a CT scan, increase the likelihood of a future coronary event such as a heart attack, angina, or death from coronary heart disease.
FDA has issued draft guidelines to aid the development, testing and manufacture of coronary drug-eluting stents, devices used to treat blocked heart arteries.
Unstable coronary plaques, that cause most heart attacks, can be identified before a heart attack occurs using noninvasive computed tomographic angiography.
Heart surgery patients who receive transfusions with blood that has been stored more than 14 days are likelier to suffer complications and may face reduced short and long-term survival.
A combination of gene variants previously associated with cholesterol levels does reflect patients' LDL and HDL levels and can signify increased risk of heart attack, stroke or sudden cardiac death.
Hispanics who have even a small amount of plaque build-up in the neck artery that supplies blood to the brain are up to four times more likely to suffer or die from a stroke or heart attack than Hispanics who do not have plaque.
Cardiac patients who have pessimistic beliefs about their recovery are twice as likely to die early than those who feel more optimistic.
Today, we can also use new technologies to monitor the success of our efforts to lower our risks for heart disease.
February is American Heart Month, and while cardiovascular disease continues to be the number one killer of Americans, many adults are confused about what foods to eat and what to avoid. A January survey of healthy adults conducted by the Egg Nutrition Center shows that nearly one out of four (24 percent) Americans still avoid eggs for fear of dietary cholesterol, even though 30 years of research has never linked egg consumption to heart disease. As a result of this myth, many Americans are missing out on the beneficial nutrients of the incredible egg.
Tryton Medical has received CE Mark approval for its Side Branch Stent. The Tryton Side-Branch Stent is a high performance cobalt chromium balloon-expandable coronary stent specifically developed for the complete treatment of the entire spectrum of coronary artery bifurcation disease. Approximately 540,000 annual procedures are performed to address bifurcation lesions, accounting for 20% of all coronary lesions treated. With the exception of Tryton's stent, no dedicated solution exists today that fully addresses these lesions.
Boston Scientific debuted an educational initiative called "Close the Gap," which is aimed at addressing disparities in cardiovascular care.